Now live: Innocentive Marketplace. Get shortlisted for funded opportunities today.

New Disease Indications for NK3 (Tachykinin Receptor 3) Antagonists

15 Submissions
$15,000 USD
Challenge closed

Challenge overview

The Seeker desires novel clinical indications for a small molecule antagonist of NK3 (neurokinin receptor 3, also known as tachykinin receptor 3).  A number of CNS clinical indications for NK3 antagonist have been considered, such as the treatment of schizophrenia and the treatment of drug addiction.  The Seeker is particularly interested in indications which can tolerate, or exploit the known pharmacological effects of a NK3 antagonists. 

This Challenge requires only a written proposal.

The Seeker desires novel clinical indications for a small molecule antagonist of NK3 (neurokinin receptor 3, also known as tachykinin receptor 3).  The tachykinin NK3 receptor is a G-protein coupled receptor coupled to the Gq (Ca2+) pathway.  The endogenous ligand is neurokinin B (NKB).   A number of CNS indications for NK3 antagonist have been considered, such as the treatment of schizophrenia and the treatment of drug addiction. 

Recent studies suggest that there is a specific lowering of sex hormones associated with of NK-3 anatagonists.  Solver submissions should propose clinical indications or patient populations which can tolerate, or exploit, the anticipated lowering of sex hormones. 

This is a Theoretical Challenge that requires only a written proposal to be submitted.  The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. 

To receive the full award, the Solvers will have to transfer to the Seeker their exclusive Intellectual Property (IP) rights to the solution.

Use the slider to explore how the Challenge process works:

Register

Review & Accept

Submit

Win

To start solving this Challenge, log in to the Challenge Center or register as a Solver